PMVP · XBRL financial data

PMV Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PMVP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	23,933	36,493	51,988	55,885	58,527	69,877
General and administrative	11,009	21,800	25,052	24,247	26,921	16,329
Total operating expenses	34,942	58,293	77,040	80,132	85,448	86,206
Operating income (loss)	(34,942)	(58,293)	(77,040)	(80,132)	(85,448)	(86,206)
Other income (expense)	508	470	3,714	11,174	10,639	6,292
Income tax expense (benefit)	6	23	(9)	2	(16,100)	(2,172)
Net income (loss)	(34,440)	(57,846)	(73,317)	(68,960)	(58,709)	(77,742)
Earnings per share, basic USD per share	(2.40)	(1.28)	(1.61)	(1.44)	(1.14)	(1.48)
Earnings per share, diluted USD per share	(2.40)	(1.28)	(1.61)	(1.44)	(1.14)	(1.48)
Weighted average shares, basic thousands of shares	14,364	45,138	45,595	48,015	51,579	52,542
Weighted average shares, diluted thousands of shares	14,364	45,138	45,595	48,015	51,579	52,542

Fiscal years (PMVP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	361,422	172,467	108,297	37,706	40,876	37,983
Marketable securities	—	124,696	132,757	165,351	128,578	74,960
Marketable securities, non-current	—	16,911	2,495	25,505	13,843	0
Prepaid and other current assets	3,339	3,301	5,130	3,530	6,204	2,284
Total current assets	364,761	301,286	247,006	207,409	175,658	115,227
Property and equipment, net	569	3,090	10,955	10,666	409	237
Right-of-use asset	—	10,060	9,539	8,382	1,143	801
Total assets	365,531	331,568	270,308	252,152	191,288	116,562
Accounts payable	1,607	3,189	2,996	3,237	6,579	3,155
Accrued liabilities	4,803	8,627	7,308	9,940	7,439	7,857
Total current liabilities	6,410	12,219	10,832	14,029	14,370	11,415
Lease liability, non-current	—	10,790	13,448	12,434	838	435
Total liabilities	6,410	23,009	24,280	26,463	15,208	11,850
Accumulated deficit	(109,880)	(167,726)	(241,043)	(310,003)	(368,712)	(446,454)
Total stockholders' equity	359,121	308,559	246,028	225,689	176,080	104,712
Total liabilities and equity	365,531	331,568	270,308	252,152	191,288	116,562
Common shares outstanding (cover page) thousands of shares	44,783	45,451	45,773	51,443	51,934	53,329

Fiscal years (PMVP's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(34,440)	(57,846)	(73,317)	(68,960)	(58,709)	(77,742)
Stock-based compensation	1,933	5,340	10,195	12,375	8,872	5,924
Net cash from operating activities	(32,739)	(46,571)	(63,760)	(55,657)	(51,282)	(73,577)
Purchases of property and equipment	148	1,349	7,984	962	655	29
Net cash from investing activities	27,911	(143,584)	(1,368)	(50,545)	53,352	70,172
Proceeds from issuing common stock	223,176	—	—	35,121	—	—
Net cash from financing activities	292,972	2,022	958	35,577	313	505
Net change in cash	288,144	(188,133)	(64,170)	(70,591)	2,348	(2,893)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
PMV Pharmaceuticals	12,469	not reported	(14,577)*	53.5M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	85,382	not reported	(19,988)*	53.6M	20.0 quarters	Q2 FY26 10-QJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.